PhytoHealth Corporation researches, develops, manufactures, and sells medicines, cosmetics, Class B medicines, complementary foods, and other related products in Taiwan. It operates in three segments: Medicines and Health Food, Medical Diagnosis, and Precision Medical Equipment and Instruments. The Medicines and Health Food segment manufactures and sells Chinese medicine materials and new drugs. The Medical Diagnosis segment develops and sells smart medical imaging diagnostic products. The Precision Medical Equipment and Instruments segment engages in the research and development, manufacturing, and sale of ultrasound probes and analysis systems. Its products under development include PHN031, which has completed Phase II clinical trials for the treatment of osteoporosis, and PHN033, which has completed Phase II clinical trials for the treatment of diabetic nephropathy. The company is also developing PHN016, which is in Phase II clinical trials for the treatment of cancer, and PHN017, which is in Phase I trials for the treatment of severe infection-induced cytokine storm. In addition, it offers PG2 Lyophilized Injection for the treatment of cancer-related fatigue and capsules for acute moderate to severe pain. PhytoHealth Corporation was incorporated in 1998 and is based in Taipei, Taiwan.
Часто задаваемые вопросы
В каком секторе работает Phytohealth Corp (4108)?
Phytohealth Corp относится к сектору Здравоохранение.
Какова текущая цена акций Phytohealth Corp (4108)?
По последним данным, цена акций Phytohealth Corp составляет 11,80 NT$, предыдущее закрытие — 11,85 NT$. За последнюю торговую сессию акции Phytohealth Corp снизились на -0,05 NT$, что соответствует падению на -0,42%.
Выплачивает ли Phytohealth Corp (4108) дивиденды?
Нет, Phytohealth Corp не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Phytohealth Corp (4108)?
У компании Phytohealth Corp бета 0.368, что указывает на более низкую волатильность по сравнению с рынком в целом.
